Accéder au contenu
Merck

Discovery of dopamine D₄ receptor antagonists with planar chirality.

Bioorganic & medicinal chemistry (2013-02-23)
Fabrizio Sanna, Birgit Ortner, Harald Hübner, Stefan Löber, Nuska Tschammer, Peter Gmeiner
RÉSUMÉ

Employing the D4 selective phenylpiperazine 2 as a lead compound, planar chiral analogs with paracyclophane substructure were synthesized and evaluated for their ability to bind and activate dopamine receptors. The study revealed that the introduction of a [2.2]paracyclophane moiety is tolerated by dopamine receptors of the D2 family. Subtype selectivity for D4 and ligand efficacy depend on the absolute configuration of the test compounds. Whereas the achiral single-layered lead 2 and the double-layered paracyclophane (R)-3 showed partial agonist properties, the enantiomer (S)-3 behaved as a neutral antagonist.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
1-Phenylpiperazine, ≥97.0%